Business Context and Reporting Period
This Form 8-K Current Report was filed by Processa Pharmaceuticals, Inc. on February 13, 2023, covering events occurring on February 9, 2023. The filing details a registered direct offering of common stock and the entry into a material definitive agreement with accredited investors.
Key Financial Metrics
- Gross Proceeds: Approximately $6.25 million.
- Net Proceeds: Approximately $5.7 million after deducting placement agent fees and estimated offering expenses.
- Shares Issued: 7,812,544 shares of common stock.
- Offering Price: $0.80 per share.
- Placement Agent Fee: 8.0% of gross proceeds (excluding insider proceeds).
- Expense Reimbursement Cap: Up to $60,000 for legal fees and other expenses.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement with certain accredited investors. The offering closed on February 14, 2023. A key material term of the agreement includes a lock-up provision: for 90 days post-closing, or until the stock price exceeds $2.00 for 10 consecutive trading days (whichever is earlier), the Company and its subsidiaries are restricted from issuing or announcing the issuance of any common stock or common stock equivalents, subject to certain exceptions.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue outlook, or management commentary regarding future operational performance. The primary risk disclosed relates to the dilution of existing shareholders due to the issuance of new shares and the temporary restriction on future equity issuances imposed by the lock-up provision. The filing explicitly states that the Purchase Agreement's representations and warranties are not intended as factual information for the public.
Investor Verification Checklist
- Verify the final closing date of the offering (stated as February 14, 2023) and confirm the actual net proceeds received.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific exceptions to the lock-up provision.
- Check subsequent filings to monitor the Company's cash burn rate and how the $5.7 million in net proceeds will be utilized.
- Confirm the identity of the accredited investors and whether any Company insiders participated in the offering.